RNXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RenovoRx Inc (RNXT) is not a strong buy at this moment for a beginner investor with a long-term horizon. While the company has potential in its FDA-cleared technology and a positive analyst rating, the lack of significant trading signals, overbought technical indicators, and weak financial performance make it prudent to hold off on investing right now.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 80.947, signaling the stock is overbought. Moving averages are converging, suggesting indecision in price direction. Key resistance levels are at 1.233 and 1.348, while support levels are at 0.858 and 0.743.
The company has an FDA-cleared dual-balloon catheter, RenovoCath, which is seen as particularly useful for treating pancreatic cancer. Analyst Justin Walsh has initiated coverage with a Buy rating and an $8 price target.
The stock is overbought based on RSI. Financial performance remains weak, with negative net income and declining EPS. There are no recent news updates or significant trading trends from hedge funds or insiders.
In Q3 2025, revenue remained flat at $266,000 YoY. Net income improved by 17.85% YoY but remains negative at -$2,912,000. EPS dropped by 20% YoY to -0.08. Gross margin is strong at 80.08% but unchanged YoY.
Analyst Justin Walsh from JonesResearch initiated coverage with a Buy rating and an $8 price target, citing the potential of RenovoCath for treating pancreatic cancer.
